SCHEMBL3387104

SCHEMBL3387104

COCOc1ccc(-c2csc3ncnc(C(N)c4ccccn4)c23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 3/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 3/20 0.42
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
FGFR1 P11362 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
DAPK3 O43293 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
LCK P06239 1/20 0.40
CSF1R P07333 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3386296 0.90 MAPT (0.55) MAPTNPSR1LMNAKMT2AMEN1
SCHEMBL2369059 0.84 FGFR1 (0.56) LMNAFGFR1HPGDHTTDAPK3
SCHEMBL3385743 0.82 HTT (0.54) MAPTNPSR1LMNAKMT2AFGFR1
SCHEMBL3387950 0.82 LMNA (0.52) MAPTNPSR1LMNAKMT2AMEN1
SCHEMBL3386600 0.82 MAP4K4 (0.43) MAPTNPSR1LMNAKMT2AMEN1
SCHEMBL2369054 0.82 MAP4K4 (0.43) MAPTNPSR1LMNAKMT2AMEN1
SCHEMBL3387850 0.81 FGFR1 (0.51) MAPTNPSR1LMNACCNCCDK8
SCHEMBL3383479 0.81 MAPT (0.39) MAPTNPSR1LMNAKMT2AMEN1
SCHEMBL3381240 0.80 LMNA (0.48) NPSR1LMNAKMT2AMEN1FGFR1
SCHEMBL3382727 0.79 KDR (0.41) MAPTNPSR1LMNAKMT2AFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 MAPT 2978/4885NPSR1 571/4885LMNA 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.